NCT01859026View on ClinicalTrials.gov

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 30, 2013

Primary Completion Date

August 22, 2019

Study Completion Date

August 22, 2019

Conditions
Lung CancerNon-Small Cell Lung Cancer
Interventions
DRUG

MEK162

Treatment as outlined in study arms.

DRUG

Erlotinib

Treatment as outlined in study arms.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Array BioPharma
All Listed Sponsors
collaborator

Array BioPharma

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01859026 - A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | Biotech Hunter | Biotech Hunter